Bruce Leuchter, CEO, Neurvati, discusses why patient engagement is essential to understanding rare diseases and driving the ...

The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient ...

In the fourth part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, explains ...

The Impact of FDA’s Ban on Compounded GLP-1s A Pharmaceutical Executive article explores how the FDA’s ban on compounded semaglutides—following stabilized supply from Novo Nordisk and Eli Lilly—has ...

In response to the rising importance of real-world evidence (RWE) in showing value to payers beyond traditional clinical ...

Bruce Leuchter, CEO, Neurvati, discusses the vital role of public participation in healthcare policy, highlighting how ...

As drug development increasingly targets multiple indications, pharma companies must make strategic branding ...

In the final part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, predicts ...

In the third part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, describes ...

Dipanwita Das, CEO and co-founder of Sorcero, chats with Pharma Commerce to dig into the evolving drug development landscape, ...

When automatically moved from a zero-dollar silver plan to one that requires a premium due to plan turnover, do lower-income ...